News About: Pharm. Industry
Hanall to conduct phase 2 trial for protein therapeutic in US
Hanall BioPharma says it has filed its phase 2 application for its lead protein product, Hanferon (interferon alpha), to the U.S. Food and Drug Administration.
If approved, the company will conduct phase 2 trial in...
Cialis increases market share
Cialis, multinational pharmaceutical firm Eli Lilly and Company’s erectile dysfunction drug, is expanding its share of the domestic anti-impotence drug market dominated by Pfizer’s Viagra, an industry report said rece...
Boryung eying sales of 100 billion won with new drug
Boryung Pharmaceutical Co. said its 74 newly recruited salespersons have been under intensive product training for Kanarb (fimasartan), a new drug for hypertension.
The company filed an application with the country...
CreaGene to initiate phase 2 study for liver cancer vaccine
CreaGene Inc., an affiliated company of Choongwae Pharm, said on September 7 that it will conduct its local phase 2 clinical trials for CreaVax-HCC Inj. in five university hospitals, including Seoul National Universit...
Green Cross, Samil to join forces in OTC products
Green Cross Corp. and Samil Pharm have agreed to join hands to market Samil’s Tiersilonce (terbinafine), a potent athlete’s foot treatment and artificial tear solution EYE2O, it was learned on September 5.
Tiersilo...
Novartis Korea executive to head Genzyme Korea
Genzyme Korea said it has recently appointed Novartis Korea’s general manager Bae Kyung-eun as the president of Genzyme Korea.
As a graduate of Seoul National University pharmacy college, Bae, 40, first joined Nova...
CJ Cheil Jedang, RaQualia join hands for acid pump antagonist
CJ Cheil Jedang said on September 3 that it has signed a licensing agreement with RaQualia Pharma Inc, a Japanese pharmaceutical venture, granting CJ exclusive rights to RaQualia’s acid pump Antagonists (RQ-00000004, ...
Korea United selected in Forbes Asia's "Best Under A Billion" list
Korea United Pharmaceutical has continued to members of Forbes Asia's "Best Under A Billion" list for the second consecutive year, even as 151 new companies have made their maiden appearance on the list this year.
...
Amosartan wins Jang Young Sil Award
Hanmi Pharm’s Amorsartan, a combination drug of amlodipine camsylate and losartan potassium, has won IR52 Jang Young Sil Award for its contribution in upgrading the country’s drug technologies and in expanding oversea...
Debate reignited over quality of vitamin
A local vitamin maker’s advertisement in a daily paper kicked off a debate over the origin of vitamin C ingredients.
The Korea Eundan claimed in the advertisement that the company is the only maker who has produced...
